JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
unknown
📅 Published: 2026-03-16 16:59
📰 Source: Yahoo
📝 Words: 23
📝 Article Content
J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as mid-to-late-stage studies advance.
📄 Summary
J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as mid-to-late-stage studies advance.
Scraping Metadata:
Scraped At:
Unknown
Created At:
2026-03-20 04:09:43
Updated At:
2026-03-20 04:09:43
Scraping Job ID:
N/A
Stock Mentions:
JNJ - Johnson & Johnson
Relevance: N/A
KEY - KeyCorp
Relevance: N/A